Autoimmune Diseases of the Nervous System
18
7
7
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
5.6%
1 terminated out of 18 trials
85.7%
-0.8% vs benchmark
11%
2 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (18)
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis
Aerobic Exercise for Remyelination in Multiple Sclerosis
JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Ukulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility Study
Biomarkers in Autoimmune Disease of Nervous System
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple Sclerosis
Power Training in Older Multiple Sclerosis Patients
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis